BDSI expects $50 million in latest public offering
Following the announcement of the $30 million acquisition of U.S. commercialization rights to a Japanese drug, Raleigh's BDSI has priced its public offering – anticipating gross proceeds of $50 million.
BioDelivery Sciences International, (Nasdaq: BDSI) recently announced the acquisition of exclusive U.S. commercial rights for Shionogi's Symproic – a drug which treats opioid-induced constipation in adult patients with chronic non-cancer pain. T he rights will cost the company $20 million…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Seth Thomas Gulledge Source Type: news
More News: Cancer & Oncology | Constipation | Health Management | Japan Health | Mergers and Aquisitions | Pain